Cargando…

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19. Here, we characterize several receptor binding domain (RBD)-specific Nbs isolated from an Nb library deri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xilin, Cheng, Lin, Fu, Ming, Huang, Bilian, Zhu, Linjing, Xu, Shijie, Shi, Haixia, Zhang, Doudou, Yuan, Huanyun, Nawaz, Waqas, Yang, Ping, Hu, Qinxue, Liu, Yalan, Wu, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492916/ https://www.ncbi.nlm.nih.gov/pubmed/34644535 http://dx.doi.org/10.1016/j.celrep.2021.109869

Ejemplares similares

Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)
por: Wu, Xilin, et al.
Publicado: (2022)

Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer
por: Huang, Bilian, et al.
Publicado: (2021)

AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
por: Nawaz, Waqas, et al.
Publicado: (2021)

Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice
por: Kumari, Pratima, et al.
Publicado: (2021)

Generation of SARS-CoV-2 Mouse Model by Transient Expression of the Human ACE2 Gene Mediated by Intranasal Administration of AAV-hACE2
por: Glazkova, D. V., et al.
Publicado: (2022)

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
por: Linsky, Thomas W., et al.
Publicado: (2020)

Abstract 2702: Highly synergistic combinations of nanobodies that target SARS-CoV-2 reduce viral load in hACE2 transgenic mice
por: Olivier, Paul, et al.
Publicado: (2023)

Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
por: Cao, Huibi, et al.
Publicado: (2021)

Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression
por: Carossino, Mariano, et al.
Publicado: (2022)

Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster
por: Zhang, Ya-Nan, et al.
Publicado: (2023)

Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection
por: Diallo, Béré K., et al.
Publicado: (2023)

Comparative pathology of the nasal epithelium in K18-hACE2 Tg mice, hACE2 Tg mice, and hamsters infected with SARS-CoV-2
por: Yu, Pin, et al.
Publicado: (2022)

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
por: Ma, Huan, et al.
Publicado: (2022)

Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
por: Misson Mindrebo, Laetitia, et al.
Publicado: (2023)

Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells
por: Wu, Xilin, et al.
Publicado: (2019)

Infection of humanized mice with a novel phlebovirus presented pathogenic features of severe fever with thrombocytopenia syndrome
por: Xu, Shijie, et al.
Publicado: (2021)

Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection
por: Americo, Jeffrey L., et al.
Publicado: (2022)

The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry
por: Zhang, Junsong, et al.
Publicado: (2021)

Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
por: Lee, Katherine S, et al.
Publicado: (2023)

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection
por: Russo, Momtchilo, et al.
Publicado: (2023)

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
por: Hao, Shuai, et al.
Publicado: (2022)

Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
por: Bai, Zixuan, et al.
Publicado: (2022)

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
por: Wang, Wei Bu, et al.
Publicado: (2021)

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2
por: Carter, Camryn, et al.
Publicado: (2023)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy
por: Bai, Xuefei, et al.
Publicado: (2021)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge
por: Wong, Ting Y., et al.
Publicado: (2022)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice
por: DeDiego, Marta L., et al.
Publicado: (2008)

COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice
por: Zheng, Jian, et al.
Publicado: (2020)

Attractive and repulsive residue fragments at the interface of SARS-CoV-2 and hACE2
por: Rodriguez, Jorge H.
Publicado: (2021)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

K18-hACE2 mice develop respiratory disease resembling severe COVID-19
por: Yinda, Claude Kwe, et al.
Publicado: (2020)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

K18-hACE2 mice develop respiratory disease resembling severe COVID-19
por: Yinda, Claude Kwe, et al.
Publicado: (2021)

Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice
por: Muturi, Elishiba, et al.
Publicado: (2022)

Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse
por: Seehusen, Frauke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8n3oc8m51jmrhcr0ben5hp9hqq